Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Shares Outstanding (Weighted Average) (2016 - 2025)

Traws Pharma (TRAW) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 13.8% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $8.2 million, up 13.8%, while the annual FY2025 figure was $8.2 million, 13.8% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $8.2 million in Q4 2025 for Traws Pharma, up from $7.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $21.0 million in Q2 2023 and bottomed at $12650.0 in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $9.6 million, with a median of $7.6 million recorded in 2021.
  • Year-over-year, Shares Outstanding (Weighted Average) tumbled 99.94% in 2023 and then soared 57059.22% in 2024.
  • Traws Pharma's Shares Outstanding (Weighted Average) stood at $16.8 million in 2021, then grew by 24.22% to $20.9 million in 2022, then crashed by 99.94% to $12650.0 in 2023, then skyrocketed by 57059.22% to $7.2 million in 2024, then rose by 13.8% to $8.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $8.2 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.